CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers

Wang, Xiaobo, Moore, Mary P., Shi, Hongxue, Miyata, Yoshinari, Donnelly, Sara K., Radiloff, Daniel R., Tabas, Ira·2023·Molecular Therapy Methods & Clinical Development
DOI 10.1016/j.omtm.2023.101165PMC PMC10746533

Published version of a preprint

Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2023.101165

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment of MASH mice with GalNAc-siTaz prevents fibrosis and inflammation in MASH.

    “we have recently used siRNA conjugated to N-acetylgalactosamine (GalNAc),96 the first FDA-approved hepatocyte-target siRNA,97 to silence hepatocyte TAZ, and found that treatment of MASH mice with GalNAc-siTaz prevents fibrosis and inflammation in MASH.98,99”

    From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [99]

  • The retromer stabilization approach may be more potent than targeting TAZ, as TAZ silencing does not alleviate steatosis.

    “This retromer stabilization approach may be more potent than targeting TAZ, as TAZ silencing does not alleviate steatosis.98,99”

    From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [99]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. Harrison, 2023, Challenges and opportunities in NASH drug development, Nat. Med., 29, 562, 10.1038/s41591-023-02242-6 · DOI · Paper page
  2. Santhekadur, 2018, Preclinical models of non-alcoholic fatty liver disease, J. Hepatol., 68, 230, 10.1016/j.jhep.2017.10.031 · DOI · Paper page
  3. Wang, 2020, Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis, Cell Metab., 31, 969, 10.1016/j.cmet.2020.03.010 · DOI · Paper page
  4. Gardin, 2022, Modern therapeutic approaches to liver-related disorders, J. Hepatol., 76, 1392, 10.1016/j.jhep.2021.12.015 · DOI
  5. Rizk, 2019, Patisiran for the treatment of patients with familial amyloid polyneuropathy, Drugs Today, 55, 315, 10.1358/dot.2019.55.5.2958475 · DOI
  6. Honor, 2021, Givosiran to treat acute porphyria, Drugs Today, 57, 47, 10.1358/dot.2021.57.1.3230207 · DOI
  7. Scott, 2021, Lumasiran: first approval, Drugs, 81, 277, 10.1007/s40265-020-01463-0 · DOI
  8. Giordano, 2023, Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent, Curr. Opin. Lipidol., 34, 133, 10.1097/MOL.0000000000000877 · DOI
  9. Wang, 2019, A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice, Hepatol. Commun., 3, 1221, 10.1002/hep4.1405 · DOI · Paper page
  10. Grompe, 2013, Mice with human livers, Gastroenterology, 145, 1209, 10.1053/j.gastro.2013.09.009 · DOI
  11. Tateno, 2015, Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice, PLoS One, 10, e0142145, 10.1371/journal.pone.0142145 · DOI
  12. Kisoh, 2021, Estimating drug efficacy with a diet-induced NASH model in chimeric mice with humanized livers, Biomedicines, 9, 1647, 10.3390/biomedicines9111647 · DOI
  13. Kelly, 2004, Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex, Proc. Natl. Acad. Sci. USA, 101, 11839, 10.1073/pnas.0404474101 · DOI
  14. Conway, 2023, Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH, Cell Rep. Med., 4, 101016, 10.1016/j.xcrm.2023.101016 · DOI
  15. Totaro, 2018, Crosstalk between YAP/TAZ and Notch signaling, Trends Cell Biol., 28, 560, 10.1016/j.tcb.2018.03.001 · DOI
  16. Touchette, 2022, Characterization and prevention of hypovitaminosis c in chimeric mice with humanized livers, Comp. Med., 72, 355, 10.30802/AALAS-CM-22-000027 · DOI
  17. Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038 · DOI · Paper page
  18. Kabbani, 2022, Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice, Cell Rep., 40, 111321, 10.1016/j.celrep.2022.111321 · DOI
  19. Moore, 2023, Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH, JHEP. Rep., 5, 100716, 10.1016/j.jhepr.2023.100716 · DOI
  20. Wang, 2021, TAZ-Induced Cybb in hepatocytes contributes to early liver tumorigenesis in experimental non-alcoholic steatohepatitis (online), J. Hepatol., 76, 910, 10.1016/j.jhep.2021.11.031 · DOI
  21. Seidman, 2020, Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis, Immunity, 52, 1057, 10.1016/j.immuni.2020.04.001 · DOI · Paper page
  22. Plouffe, 2018, The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell, J. Biol. Chem., 293, 11230, 10.1074/jbc.RA118.002715 · DOI
  23. Lonardo, 2019, Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps, Hepatology, 70, 1457, 10.1002/hep.30626 · DOI
  24. Griffin, 2016, Sexually dimorphic myeloid inflammatory and metabolic responses to diet-induced obesity, Am. J. Physiol. Regul. Integr. Comp. Physiol., 311, R211, 10.1152/ajpregu.00136.2016 · DOI
  25. Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat. Genet., 40, 1461, 10.1038/ng.257 · DOI · Paper page
  26. Wei, 2020, Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer, Am. J. Physiol. Gastrointest. Liver Physiol., 318, 10.1152/ajpgi.00041.2019 · DOI · Paper page
  27. Debacker, 2020, Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug, Mol. Ther., 28, 1759, 10.1016/j.ymthe.2020.06.015 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Wang, X., Moore, M. P., Shi, H., Miyata, Y., Donnelly, S. K., Radiloff, D. R., & Tabas, I.
Venue
Molecular Therapy Methods & Clinical Development
Publisher
Elsevier BV
Published
2023-12
Volume
31
Pages
101165
ISSN
2329-0501
DOI
10.1016/j.omtm.2023.101165
PMC
PMC10746533
Cited by
21
References
6
Language
en
Licence
Funders
Takeda Pharmaceutical Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review